Unknown

Dataset Information

0

Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.


ABSTRACT: This study sought to investigate the efficacy of duloxetine for the treatment of obsessive-compulsive disorder (DSM-IV).Twenty individuals were enrolled in a 17-week, open-label trial of duloxetine at Massachusetts General Hospital. Data were collected between March 2007 and September 2012. Study measures assessing obsessive-compulsive disorder symptoms, quality of life, depression, and anxiety were administered at baseline and weeks 1, 5, 9, 13, and 17. The primary outcome measures were the Yale-Brown Obsessive Compulsive Scale and Clinical Global Improvement scale.For the 12 study completers, pre- and posttreatment analyses revealed significant improvements (P<.05) on clinician- and self-rated measures of obsessive-compulsive disorder symptoms and quality of life. Among the 12 completers, more than one-half (n=7) satisfied full medication response criteria. Intention-to-treat analyses (n=20) showed similar improvements (P<.05) on primary and secondary study outcome measures.The results of this study suggest that duloxetine may provide a significant reduction in symptoms for patients with obsessive-compulsive disorder. ClinicalTrials.gov NCT00464698; http://clinicaltrials.gov/ct2/show/NCT00464698?term=NCT00464698&rank=1.

SUBMITTER: Dougherty DD 

PROVIDER: S-EPMC4368895 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.

Dougherty Darin D DD   Corse Andrew K AK   Chou Tina T   Duffy Amanda A   Arulpragasam Amanda R AR   Deckersbach Thilo T   Jenike Michael A MA   Keuthen Nancy J NJ  

The international journal of neuropsychopharmacology 20150130 2


<h4>Background</h4>This study sought to investigate the efficacy of duloxetine for the treatment of obsessive-compulsive disorder (DSM-IV).<h4>Methods</h4>Twenty individuals were enrolled in a 17-week, open-label trial of duloxetine at Massachusetts General Hospital. Data were collected between March 2007 and September 2012. Study measures assessing obsessive-compulsive disorder symptoms, quality of life, depression, and anxiety were administered at baseline and weeks 1, 5, 9, 13, and 17. The pr  ...[more]

Similar Datasets

| S-EPMC7375126 | biostudies-literature
| S-EPMC3181958 | biostudies-literature
| S-EPMC7059159 | biostudies-literature
| S-EPMC3109740 | biostudies-literature
| PRJNA588485 | ENA
| PRJNA588486 | ENA
| S-EPMC7370844 | biostudies-literature
| S-EPMC4511269 | biostudies-literature
| S-EPMC5500971 | biostudies-literature
| S-EPMC4517847 | biostudies-literature